Understanding How Labour Trafficking Networks Exploit Systemic Vulnerabilities in Europe: An Exploration of the Italian Agriculture Sector

La tratta degli esseri umani a scopo di sfruttamento lavorativo (tratta lavorativa, labour trafficking) in Europa è un grave crimine contro le persone, che viola i diritti umani. La ricerca esistente si concentra principalmente sulle vittime, mentre lo studio degli autori di reato e sul modo in cui sfruttano le vulnerabilità del sistema è meno sviluppato. Questo è dovuto in parte alla mancanza di dati robusti, ma anche a un approccio della ricerca criminologica tradizionalmente rigido e settoriale. Al contrario, lo studio della tratta lavorativa richiede concetti flessibili, che riconoscano le radici profonde di questo fenomeno nell’intero sistema socioeconomico, più che il semplice prodotto della volontà degli autori dei reati. Partendo dalle indicazioni della letteratura, questa ricerca si concentra sul settore agricolo italiano, non ancora esaminato da un punto di vista criminologico. L’obiettivo è la comprensione dei meccanismi attraverso i quali la tratta lavorativa nasce e si sviluppa. La scelta del contesto dello studio è dovuta alle caratteristiche peculiari dell’Italia, che rendono la tratta lavorativa in agricoltura centrale per il dibattito nazionale. Inoltre, l'Italia condivide alcune caratteristiche con altri paesi europei, e dunque alcune lezioni apprese da questo caso possono essere discusse alla luce del dibattito internazionale. In primo luogo, un’analisi a livello macro esamina come i fattori strutturali associati nella letteratura internazionale alla tratta lavorativa si concretizzano nel contesto italiano. I risultati mostrano che il sistema stesso sembra creare un terreno fertile per lo sviluppo e il mantenimento della tratta lavorativa: la vulnerabilità dei lavoratori migranti è insita nell'attuale quadro normativo dell’immigrazione; la filiera agroalimentare impone ai produttori la riduzione del costo della forza lavoro; e l'attuale sistema legale basato sulla repressione delle condotte criminose inquadrate come eventi eccezionali è insufficiente. In secondo luogo, un’analisi a livello meso descrive le caratteristiche generali delle reti della tratta lavorativa in Italia. Quattro casi studio selezionati con un metodo razionale e sistematico sono poi approfonditi per identificare le principali caratteristiche, modalità e organizzazione relazionale dei reati, e i metodi con cui viene sviluppata e mantenuta la condizione di sfruttamento delle vittime. I risultati mostrano che nei quattro casi studio le reti si sviluppano e si adattano alle opportunità offerte dal sistema legale. I risultati e gli insegnamenti tratti dal caso italiano sono infine discussi alla luce del dibattito internazionale sulla tratta lavorativa.Labour trafficking in Europe is a serious crime against persons, violating their fundamental human rights. Existing research primarily focuses on the victims, while data on offenders and the manner in which they exploit vulnerabilities is less developed. Recent trends in criminological literature are highlighting how the past lack of research is related to the lack of robust data, but also to traditional rigid approaches with exception to few extreme cases. On the contrary, they call for more flexible concepts recognising that labour trafficking is not only the product of offenders’ will, but has deep roots embedded in the socioeconomic system. Elaborating on these indications, this research focuses on the Italian agriculture sector, which has not yet been examined in literature from a criminological perspective, with the aim to understand the mechanisms through which labour trafficking originates and develops. This choice has been made because the characteristics particular to Italy make labour trafficking in agriculture central to the debate within the country; and because Italy shares some characteristics with other European countries, so some lessons learnt from this case can be discussed in light of the international debate on labour trafficking. First, a macro-analysis examines how the structural factors associated in the international literature with labour trafficking take shape in the Italian context. The results show that the system itself seems to create a fertile ground for labour trafficking to develop and maintain: migrant workers’ vulnerability is inherent in the current migration regulatory framework; the agrifood supply chain makes it necessary for producers to lower the cost of workforce; and the current legal system based on the repression of abusive conducts seen as exceptional events proves ineffective. Second, a meso-analysis at organisation/network level describes the general characteristics of labour trafficking networks in Italy, and then zooms in four case studies selected through a rational systematic method to identify the main features, modalities, and relational organisation of the crime commission, and how the exploitative condition of the victims is developed and maintained. The results show that in the four case studies the trafficking networks develop and adapt to the opportunities offered by the legal system. The results are finally discussed in light of the international debate on labour trafficking, and the lessons learned from the case of Italy

Recruitment into organised criminal groups: A systematic review

This paper provides a narrative synthesis of the results of a systematic review of the social, psychological and economic factors leading to recruitment into organised crime. This is based on the analysis of evidence emerging from 47 qualitative, quantitative and mixed-method studies published in or before 2017. While the selected studies varied markedly in method and quality, several factors emerged as particularly important in understanding recruitment into organised criminal groups. These included the role of social relations (family, kinship, friendship and work-relations), criminal background and criminal skills

MOLNUPIRAVIR COMPARED TO NIRMATRELVIR/RITONAVIR FOR COVID-19 IN HIGH-RISK PATIENTS WITH HAEMATOLOGICAL MALIGNANCY IN EUROPE. A MATCHED-PAIRED ANALYSIS FROM THE EPICOVIDEHA REGISTRY

Introduction: Molnupiravir and nirmatrelvir/ritonavir are antivirals used to prevent progression to severe SARS-CoV-2 infections, which reduce both hospitalization and mortality rates. Nirmatrelvir/ritonavir was authorised in Europe in December 2021, while molnupiravir is not yet licensed in Europe as of February 2022. Molnupiravir may be an alternative to nirmatrelvir/ritonavir, because it displays less frequent drug-drug interactions and contraindications. A caveat connected to molnupiravir derives from the mode of action inducing viral mutations. In clinical trials on patients without haematological malignancy, mortality rate reduction of molnupiravir appeared less pronounced than that of nirmatrelvir/ritonavir. Little is known about the comparative efficacy of the two drugs in patients with haematological malignancy at high-risk of severe COVID-19. Thus, we here assess the effectiveness of molnupiravir compared to nirmatrelvir/ritonavir in our cohort of patients with haematological malignancies. Methods: Clinical data of patients treated either with molnupiravir or nirmatrelvir/ritonavir monotherapy for COVID-19 were retrieved from the EPICOVIDEHA registry. Patients treated with molnupiravir were matched by sex, age (±10 years), and baseline haematological malignancy severity to controls treated with nirmatrelvir/ritonavir. Results: A total of 116 patients receiving molnupiravir for the clinical management of COVID-19 were matched to an equal number of controls receiving nirmatrelvir/ritonavir. In each of the groups, 68 (59%) patients were male; with a median age of 64 years (IQR 53-74) for molnupiravir recipients and 64 years (IQR 54-73) for nirmatrelvir/ritonavir recipients; 57% (n=66) of the patients had controlled baseline haematological malignancy, 13% (n=15) stable, and 30% (n=35) had active disease at COVID-19 onset in each of the groups. During COVID-19 infection, one third of patients from each group were admitted to hospital. Although a similar proportion of vaccinated patients was observed in both groups (molnupiravir n=77, 66% vs nirmatrelvir/ritonavir n=87, 75%), those treated with nirmatrelvir/ritonavir had more often received four doses (n=27, 23%) as compared to patients treated with molnupiravir (n=5, 4%, p<0.001). No differences were detected in COVID-19 severity (p=0.39) or hospitalization (p=1.0). No statistically significant differences were identified in overall mortality rate (p=0.78) or in survival probability (d30 p=0.19, d60 p=0.67, d90 p=0.68, last day of follow up p=0.68). In all patients, deaths were either attributed to COVID-19 or the infection contributed to death as per treating physician's judgement. Conclusions: In high-risk patients with haematological malignancies and COVID-19, molnupiravir showed rates of hospitalization and mortality comparable to those of nirmatrelvir/ritonavir in this matched-pair analysis. Molnupiravir appears to be a plausible alternative to nirmatrelvir/ritonavir for COVID-19 treatment in patients with haematological malignancy

Age, Successive Waves, Immunization, and Mortality in Elderly COVID-19 Haematological Patients: EPICOVIDEHA Findings

Introduction: elderly patients with haematologic malignancies face the highest risk of severe COVID-19 outcomes. The infection impact in different age groups remains unstudied in detail. Methods: We analysed elderly patients (age groups: 65-70, 71-75, 76-80 and >80 years old) with hematologic malignancies included in the EPICOVIDEHA registry between January 2020 and July 2022. Univariable and multivariable Cox regression models were conducted to identify factors influencing death in COVID-19 patients with haematological malignancy. results: the study included data from 3,603 elderly patients (aged 65 or older) with haematological malignancy, with a majority being male (58.1%) and a significant proportion having comorbidities. The patients were divided into four age groups, and the analysis assessed COVID-19 outcomes, vaccination status, and other variables in relation to age and pandemic waves.tThe 90-day survival rate for patients with COVID-19 was 71.2%, with significant differences between groups. The pandemic waves had varying impacts, with the first wave affecting patients over 80 years old, the second being more severe in 65-70, and the third being the least severe in all age groups. factors contributing to 90-day mortality included age, comorbidities, lymphopenia, active malignancy, acute leukaemia, less than three vaccine doses, severe COVID-19, and using only corticosteroids as treatment. Conclusions: These data underscore the heterogeneity of elderly haematological patients, highlight the different impact of COVID waves and the pivotal importance of vaccination, and may help in planning future healthcare efforts

Terrorism, online propaganda.

While many international corporations have benefited from the global economy and distribution of information, globalization has also had serious negative consequences. This important reference work offers students and general readers a critical understanding of how technology, governments, political unrest, war, and economic strife contribute to an increase in global crime. This A\u2013Z encyclopedia covers key people, events, and organizations and includes key documents that will help readers to understand the numerous problems created by the many transnational crimes that are growing in severity and frequency around the world. Entries address perpetrators and their methods; victims; who really profits; and law enforcement responses. In addition to cyber theft and sales of weapons and narcotics, the set provides a detailed look at global crimes not typically covered, such as corruption, fraudulent medicine, illegal sports betting, organ trafficking, maritime piracy, trafficking in cultural property, and wildlife and forest crime. Although some historical events and people are included, the focus is on recent and contemporary topics

Oligonucleotides: Current Trends and Innovative Applications in the Synthesis, Characterization, and Purification

Oligonucleotides (ONs) are gaining increasing importance as a promising novel class of biopharmaceuticals. Thanks to their fundamental role in gene regulation, they can be used to develop custom-made drugs (also called N-to-1) able to act on the gene expression at pre-translational level. With recent approvals of ON-based therapeutics by the Food and Drug Administration (FDA), a growing demand for high-quality chemically modified ONs is emerging and their market is expected to impressively prosper in the near future. To satisfy this growing market demand, a scalable and economically sustainable ON production is needed. In this paper, the state of the art of the whole ON production process is illustrated with the aim of highlighting the most promising routes toward the auspicated market-size production. In particular, the most recent advancements in both the upstream stage, mainly based on solid-phase synthesis and recombinant technology, and the downstream one, focusing on chromatographic techniques, are reviewed. Since ON production is projected to expand to the large scale, automatized multicolumn countercurrent technologies will reasonably be required soon to replace the current ones based on batch single-column operations. This consideration is supported by a recent cutting-edge application of continuous chromatography for the ON purification

Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience

COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important

Table_1_Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience.docx

COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL, the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important.</p

Image_2_Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience.jpeg

COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL, the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important.</p

Table_2_Immunogenicity of SARS-CoV-2 vaccination in patients undergoing autologous stem cell transplantation. A multicentric experience.docx

COVID-19 disease has a strong impact on hematological patients; those receiving autologous hematopoietic stem cell transplantation (aHSCT) represent a particularly vulnerable group, in which the effectiveness of vaccination is very variable. Chiarucci et al. showed that patients affected by non-Hodgkin lymphoma (NHL) and treated with rituximab experienced a lower rate of immunization against SARS-CoV-2 (54%), as well as significantly lower IgG antibody titers. In our multicenter retrospective observational study, we included 82 patients who underwent aHSCT, divided into two groups: 58 patients vaccinated after aHSCT (group A) and 24 vaccinated before getting transplantation (group B). In group A, 39 (67%) patients had positive serology, and the rate of positivity increased with time after aHSCT. In the subgroup of patients with NHL, the administration of rituximab predicted negative serology, particularly when administered in the 6 months before vaccination (13% response rate). Patients affected by plasma cells had a higher rate of positivity (83% overall), independently of the time to aHSCT. In group B, no patient who initially showed positive serology became negative after transplantation, so the aHSCT did not affect the response to the vaccination. Our study confirmed the role of rituximab as a negative predictor of response to SARS-CoV-2 vaccination, whereas the conditioning and transplantation procedure itself seemed to be less important.</p